Could a tweaked stem cell transplant free patients from a lifetime of pills?
NCT ID NCT04678401
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This early-phase study tests a new way to do stem cell transplants for people with aggressive or returning acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially processed donor cells to reduce the risk of graft-versus-host disease, aiming to eliminate the need for lifelong immunosuppressive drugs. About 30 participants will receive chemotherapy, radiation, and the experimental cell therapy to see if it is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.